"a technology toreliably deliver 7D10 into cells has not previously been identified. Patrys and itscollaborators and Yale University have shown that PAT-DX1 is targeted to tumors and can enter and kill cancer cells."
Most drugs can only attach themselves to cancer cells but are only mildly effective , patrys have the technology to enter and kill cancer cells.
PAB valuation should be much higher imo on this technology alone. The partnering and licencing potential is enormous.
Ann: Collaboration with WEHI, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |